Skip to content

Research at St Andrews

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

Research output: Contribution to journalArticle

DOI

Open Access permissions

Open

Author(s)

Stephen H. Gillespie, Angela M. Crook, Timothy D. McHugh, Carl M. Mendel, Sarah K. Meredith, Stephen R. Murray, Frances Pappas, Patrick P.J. Phillips, Andrew J. Nunn

School/Research organisations

Abstract

Background: Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month treatment of uncomplicated, smear-positive pulmonary tuberculosis.
Methods: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to test the noninferiority of two moxifloxacin-containing regimens as compared with a control regimen. One group of patients received isoniazid, rifampin, pyrazinamide, and ethambutol for 8 weeks, followed by 18 weeks of isoniazid and rifampin (control group). In the second group, we replaced ethambutol with moxifloxacin for 17 weeks, followed by 9 weeks of placebo (isoniazid group), and in the third group, we replaced isoniazid with moxifloxacin for 17 weeks, followed by 9 weeks of placebo (ethambutol group). The primary end point was treatment failure or relapse within 18 months after randomization.
Results: Of the 1931 patients who underwent randomization, in the per-protocol analysis, a favorable outcome was reported in fewer patients in the isoniazid group (85%) and the ethambutol group (80%) than in the control group (92%), for a difference favoring the control group of 6.1 percentage points (97.5% confidence interval [CI], 1.7 to 10.5) versus the isoniazid group and 11.4 percentage points (97.5% CI, 6.7 to 16.1) versus the ethambutol group. Results were consistent in the modified intention-to-treat analysis and all sensitivity analyses. The hazard ratios for the time to culture negativity in both solid and liquid mediums for the isoniazid and ethambutol groups, as compared with the control group, ranged from 1.17 to 1.25, indicating a shorter duration, with the lower bounds of the 95% confidence intervals exceeding 1.00 in all cases. There was no significant difference in the incidence of grade 3 or 4 adverse events, with events reported in 127 patients (19%) in the isoniazid group, 111 (17%) in the ethambutol group, and 123 (19%) in the control group.
Conclusions: The two moxifloxacin-containing regimens produced a more rapid initial decline in bacterial load, as compared with the control group. However, noninferiority for these regimens was not shown, which indicates that shortening treatment to 4 months was not effective in this setting. (Funded by the Global Alliance for TB Drug Development and others; REMoxTB ClinicalTrials.gov number, NCT00864383.)
Close

Details

Original languageEnglish
Pages (from-to)1577-1587
Number of pages11
JournalNew England Journal of Medicine
Volume371
Issue number17
Early online date7 Sep 2014
DOIs
Publication statusPublished - 23 Oct 2014

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy.

    Research output: Contribution to journalArticle

  2. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  3. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

  4. Molecular bacterial load assay (MBLA) concurs with culture on the NaOH-induced Mycobacterium tuberculosis loss of viability

    Mtafya, B., Sabiiti, W., Sabi, I., John, J., Sichone, E., Ntinginya, N. E. & Gillespie, S. H., 25 Jun 2019, In : Journal of Clinical Microbiology. 57, e01992-18.

    Research output: Contribution to journalArticle

  5. Heat-inactivation renders sputum safe and preserves Mycobacterium tuberculosis RNA for downstream molecular tests

    Sabiiti, W., Azam, K., Esmeraldo, E., Bhatt, N., Rachow, A. & Gillespie, S. H., Mar 2019, In : Journal of Clinical Microbiology. 57, 4, 8 p., e01778-18.

    Research output: Contribution to journalArticle

Related by journal

  1. Five-year outcomes of a randomized trial of treatments for varicose veins

    Brittenden, J., Cooper, D., Dimitrova, M., Scotland, G., Cotton, S. C., Elders, A., MacLennan, G., Ramsay, C. R., Norrie, J., Burr, J. M., Campbell, B., Bachoo, P., Chetter, I., Gough, M., Earnshaw, J., Lees, T., Scott, J., Baker, S. A., Tassie, E., Francis, J. & 1 othersCampbell, M. K., 5 Sep 2019, In : New England Journal of Medicine. 381, p. 912-922

    Research output: Contribution to journalArticle

  2. Canakinumab for atherosclerotic disease

    MRC-ILA Heart investigators, Rothman, A. M., Morton, A. C. & Crossman, D. C., 11 Jan 2018, In : New England Journal of Medicine. 378, 2, p. 197-8 2 p.

    Research output: Contribution to journalArticle

  3. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa

    Hakim, J., Musiime, V., Szubert, A. J., Mallewa, J., Siika, A., Agutu, C., Walker, S., Pett, S. L., Bwakura-Dangarembizi, M., Lugemwa, A., Kaunda, S., Karoney, M., Musoro, G., Kabahenda, S., Nathoo, K., Maitland, K., Griffiths, A., Thomason, M. J., Kityo, C., Mugyenyi, P. & 5 othersPrendergast, A. J., Walker, A. S., Gibb, D. M., REALITY Trial Team & O'Hare, B. A-M., 20 Jul 2017, In : New England Journal of Medicine. 377, 3, p. 233-245 13 p.

    Research output: Contribution to journalArticle

  4. Safer prescribing - a trial of education, informatics, and financial incentives

    Dreischulte, T., Donnan, P., Grant, A., Hapca, A., McCowan, C. & Guthrie, B., 17 Mar 2016, In : New England Journal of Medicine. 374, 11, p. 1053-1064

    Research output: Contribution to journalArticle

  5. Therapy for Tuberculous Meningitis

    Boeree, M. J., Gillespie, S. H., Hoelscher, M. & PanACEA core team, 2 Jun 2016, In : New England Journal of Medicine. 374, 22, p. 2187-8 2 p.

    Research output: Contribution to journalLetter

ID: 147208418